Frequently Asked Questions
› What is Myristol?
Myristol is a combination of 4 joint health ingredients: an omega-5 fatty acid (cetyl myristoleate), glucosamine HCl, MSM, and a mixture of individual and short chain amino acids (hydrolyzed collagen). Each ingredient supports joint health in its own unique way. The combination of ingredients was selected with this comprehensive approach in mind (to have a single product that addressed the many different facets of joint inflammation and disease).
Myristol was designed to optimize the activity of 4 different ingredients that have been shown to support joint health. Together this combination targets the many different aspects of joint disease, rather than simply having an effect on isolated components of the problem.
• Cetyl myristoleate (CM) is the cetyl alcohol ester of myristoleic acid, and is a 14-carbon monounsaturated omega-5 fatty acid. The precise mechanism of action of CM is unknown, but different hypotheses have been proposed. Standard polyunsaturated fatty acids (PUFA’s) are known to be effective at relieving inflammation. These include the omega-3 fatty acids derived from the so-called ‘good oils’, such as flaxseed oil, evening primrose oil, and the cold-water fish oils. These fatty acids help regulate production of the ‘favorable’ 1st and 3rd series prostaglandins, versus the pro-inflammatory 2nd series prostaglandins. It is possible that this is also one mechanism of action for CM.
It is also possible that CM modulates the effects of pro-inflammatory cytokines. There has also been a more recent suggestion that omega-5 fatty acids may form oxygenated metabolites through transcellular processing, and that these metabolites exert anti-inflammatory effects distinct from eicosanoids. Results from another study suggest that myristoleic acid (CM) may act through inhibition of 5-lipoxygenase, a potent mediator of inflammation.
One difference between the effects of PUFA’s and CM is that CM appears to have much longer lasting effects. It has been suggested that this derives from a ‘reprogramming’ of T cells through a process called N-myristoylation, whereby specific membrane protein receptors are activated. This may initiate intracellular signals that alter effector cell behaviors, including effects on inflammatory activities, immune function and pain responses. Further work will likely identify specific effects attributable to CM.
• Glucosamine HCl is an amino sugar that is a precursor or building block for the matrix glycosaminoglycans (GAG’s) that gives articular cartilage its stiffness when exposed to load (weightbearing). The efficacy of glucosamine has been documented in numerous human and animal studies.
• MSM is a sulfur source, and sulfur is an important component of the matrix GAG’s. MSM also has anti-inflammatory properties and has shown efficacy at relieving some muscle discomfort.
• Hydrolyzed collagen provides the building blocks for production of the specialized type II collagen present only in articular cartilage. In a recent study, it was convincingly demonstrated that the hydrolyzed collagen used in Myristol stimulated chondrocytes (cartilage cells) to produce more of this type II collagen unique to articular cartilage. Other collagen and amino acid preparations were unsuccessful at stimulating chondrocytes.
In a recent equine study, a commercial amino acid blend was shown to improve clinical signs in horses with soreness originating in their hock joints. The combination of amino acids in Myristol is equivalent to between double and triple strength of this commercial product.
Studies are available on all of the individual ingredients in Myristol, and a partial list of those references follows under each (or the most closely related) categories. Also a separate clinical trial on equine Myristol has been completed and those study results were presented at the American Association of Equine Practitioners (AAEP) veterinary meeting in Orlando, FL in December 2007 (Keegan K, Hughes F, Lane T, Buonomo F, Downer J: Effects of an oral nutraceutical on clinical aspects of joint disease in a blinded, controlled clinical trial: 39 horses. Proceedings AAEP 2007; 53: 252-255). A canine clinical trial was initiated in December 2009. Results of that trial will be presented and published when they become available.
• Cetyl Myristoleate
Myristol is effective in helping animals already affected with joint disease. However, it also plays a major role when given to young, active athletes as a preventive supplement. Given as a preventive supplement, it may reduce or eliminate the need for joint injections, or the need for other anti-inflammatory medication that may have negative side effects.
At this time, there are no known toxicities to this product. In some dogs, glucosamine administration has been associated with gastrointestinal upset, that resolves with discontinuation of feeding glucosamine. Glucosamine has also been associated with increased thirst and urination in some dogs, which also disappears with discontinuation of intake. Myristol is not intended for use in ruminant animals.
Because of the numerous active ingredients in Myristol, it will cost more than some supplements. Please browse our online store for specific sizes and pricing.
If your veterinarian is not familiar with Myristol, please have them call us at (800) 525-8602. They can also email questions to email@example.com.
There are no known negative interactions to this product at this time. However, if Myristol is effective in your animal, you may find that other supplements or pharmaceuticals are unnecessary. It is certainly unnecessary to give additional glucosamine or MSM to animals on Myristol. Also, some dogs currently receiving Rimadyl may be able to have the doseage reduced, or administration eliminated, if they respond favorably to Myristol.
If your animal suffers from chronic severe joint disease, a loading dose may be required for a 2-week period. However the concentration of ingredients in Myristol are such that for most animals, a loading dose will not be required.
As with many supplements and medications, individual variation exists. Most animals show positive results within 3 weeks, and many (particularly older dogs and horses) will show improvement within 1 week. If no positive results have been seen within 6-8 weeks, Myristol is unlikely to be effective over a longer administration period.
There are no known problems with either pregnancy or with fertility.
No. Myristol is available through this store, or through your veterinarian.
If you are a veterinarian, you can either call (800) 525-8602, or browse through our store. You can also enroll as a participating veterinarian. This will ensure that if one of your clients decides to order online, you can also participate in that sale. If you have Myristol available for purchase in your clinic or practice, you can either order online, or call (800) 525-8602.
No. Despite what some other companies have suggested regarding heat damage with pelleting, all of the ingredients in Myristol are known to be heat stable at temperatures much higher than those used in the pelleting process.
Yes. The cetyl myristoleate (CM) in Myristol derives from beef tallow. This is the same beef tallow CM source that is used in many human joint health products. Some facts about beef tallow and BSE include the fact that beef tallow shipments across the USA/Canada border were never curtailed even after BSE was discovered in a cow in Canada a couple of years ago. Beef tallow has many uses in human nutritional products, and is not considered an ‘at risk’ foodstuff. One of the very positive features about this tallow source of CM (versus so-called ‘safe’ plant sources of CM) is that the tallow source provides 40% active ingredients vs. the 15% active ingredients for plant source CM. This allows Myristol to contain a much higher level of active CM ingredients per unit of raw material than can be derived from plant source products.
The hydrolyzed collagen in Myristol is derived from porcine skin. Again, this ingredient is used in many human foodstuffs as well as certain human joint health products.
An equine clinical trial on 39 horses was presented by Dr. Kevin Keegan of the University of Missouri at the December 2007 American Association of Equine Practitioners (AAEP) meeting in Orlando, FL. You can view that study by clicking here. A canine clinical trial was initiated in December 2008 and trial results will be presented once they become available.
Because of the concentrations of the numerous active ingredients in Myristol, it will cost more than some supplements. You can get sizes and pricing by browsing our store.
That is a good question in that poor quality manufacturing, and failure to meet label claim, still represent one of the less-appealing aspects of the supplement industry in general. Fortunately there are many reputable companies, and one means of determining the quality of a company is whether it has subjected itself to the rigorous requirements for membership in the NASC (National Animal Supplement Council). This organization audits members for their standards, methods and quality of manufacturing. The presence of the NASC logo on a product indicates that that level of quality has been achieved.